Intranasal corticosteroids mitigate loss of smell in chronic rhinosinusitis with COVID-19

Doctors should consider intranasal corticosteroids for patients with chronic rhinosinusitis who also have COVID-19 to minimize loss of olfactory function, according to a study published in Allergy and Asthma Proceedings.
This use of intranasal corticosteroids (INCs) does not aggravate the clinical course of COVID-19, Can Tuzer, MD, of the department of internal medicine’s division of immunology and allergic diseases at the Istanbul Faculty of Medicine, Istanbul University, and colleagues wrote.
The researchers recruited 71 patients (median age, 39 years; interquartile range, 26-47; 62%

Doctors should consider intranasal corticosteroids for patients with chronic rhinosinusitis who also have COVID-19 to minimize loss of olfactory function, according to a study published in Allergy and Asthma Proceedings.
This use of intranasal corticosteroids (INCs) does not aggravate the clinical course of COVID-19, Can Tuzer, MD, of the department of internal medicine’s division of immunology and allergic diseases at the Istanbul Faculty of Medicine, Istanbul University, and colleagues wrote.
The researchers recruited 71 patients (median age, 39 years; interquartile range, 26-47; 62%